Akari Therapeutics amends CEO pay: salary raised to $625,000, bonus target to 55%
On September 29, 2026, Akari Therapeutics amended the Chief Executive Officer Agreement with CEO Abizer Gaslightwala. The amendment raises his base salary from $475,000 to $625,000 effective August 18, 2026, increases his target bonus to 55% of base salary, and grants options on 174,000 ADSs, with parts of the package tied to shareholder approval of a plan amendment.
Key points
- Base salary rises from $475,000 to $625,000, effective August 18, 2026; $62,500 of it is delivered as RSUs instead of cash over 12 months
- Target annual bonus increases from 50% to 55% of base salary, for target base salary and bonus of approximately $970,000
- Options to purchase 174,000 ADSs granted as of August 18, 2026, vesting monthly over four years from March 18, 2026
- RSUs and option grants depend on shareholder approval of an increase to the ADSs reserved under the 2023 Plan
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.